SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?


To: aknahow who wrote (4924)11/28/1997 9:22:00 PM
From: Robert K.  Read Replies (2) | Respond to of 17367
 
I am glad someone made money in enmd. Howwever I see nothing special about what the did. There are at least 20 compounds in development for angiogenesis. Entremeds is pre-clinical. A bit premature perhaps. Xoma has been playing with bpi anti-angiogenesis properties since at least 1994. We know bpi is generally safe. We may see something.